Metformin dual-targets metabolism and survival pathways in BPDCN - PubMed
4 hours ago
- #Metformin
- #BPDCN
- #Cancer Metabolism
- Metformin reduces cell viability and induces caspase-dependent apoptosis in BPDCN cells.
- Mechanistically, metformin activates AMPK and disrupts mitochondrial respiration and glycolysis.
- Metformin inhibits key oncogenic pathways: Akt/mTOR, NF-κB, STAT3, and STAT5.
- In vivo, metformin reduces tumor infiltration in the spleen and modulates NF-κB and STAT5 signaling.
- Overall, metformin dual-targets metabolism and survival pathways in BPDCN, supporting its therapeutic potential.